British pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read more
In a strategic move to bolster its global supply of antibody-drug conjugates (ADCs), AstraZeneca has announced the development of a
Read more
The US FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first tumor-agnostic HER2-directed therapy for the
Read more
AbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read more
In a significant milestone for the pharmaceutical industry, Merck KGaA has established itself as the pioneer Contract Testing, Development, and
Read more
Eisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read more
Pharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read more
The CTAT Enzymatic Antibody Drug Conjugation Technology -Benefits for Diagnostic Applications and ADC’s for Oncology. A EUCODIS Bioscience Case Study
Read more
Darmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read more